GTC Biotherapeutics (fka GTCB)

[gym gravity]

and this is the reason not to short them, they can make money doing other recombinant stuff, (unless india's policies change, or the cost they could get in india goes up):

The company has successfully launched bio-similar products like Neukine (rHu G-CSF), Erykine and Epofit (rHu EPO), Intalfa (rHu IFN Alfa-2b), and Neupeg (Pegylated rHu G-CSF). According to Mani Iyer, Executive Director, IBPL, "Our bottom line sales have been strong throughout past fiscal. With the launch of Neupeg (Peg Filgrastim), we have gained monopoly in the domestic market in terms of being sole manufacturers of Peg Filgrastim in India. With an array of oncology products and new sales strategy in place for current fiscal, we are looking to grab major market share in the oncology segment."

And realy, they could end up a partner to gtcb for something, in a not so distant future.